A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
The primary objective of this study is to evaluate the long-term safety and tolerability of
 ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary
 objective of this study is to evaluate treatment effect over time in adult participants with
 RRMS treated with ALKS 8700.
Key Inclusion Criteria:

 -  Has a confirmed diagnosis of RRMS

 -  Neurologically stable with no evidence of relapse within 30 days prior to Visit 2

 Exclusion Criteria:

 -  Subject is pregnant or breastfeeding or plans to become pregnant or begin
 breastfeeding at any point during the study and for 30 days after any study drug
 administration

 -  Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS

 -  History of clinically significant cardiovascular, pulmonary, gastrointestinal,
 dermatologic, psychiatric, neurologic (other than MS), and/or other major disease that
 would preclude participation in a clinical trial

 -  History of a myocardial infarction, including a silent myocardial infarction
 identified on ECG, or unstable angina

 NOTE: Other protocol defined Includison/Exclusion criteria may apply.